Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x60px

News > All

Total search results: 9825 | Ordered by Source (ascending)
1 2 3 ... 97 98 99  next pagenext page

order ascendingorder descendingSource order ascendingorder descendingDate
23andMe, Inc.. (1/28/09). "Press Release: 23andMe and mondoBIOTECH Partner to Advance Research of Rare Diseases". Davos. 2009-01-28
3B Pharmaceuticals GmbH. (11/20/18). "Press Release: Ipsen and 3BP Announce First Patient Dosed in Phase I/II Study for First-in-class Radionuclide (IPN01087)". Paris. 2018-11-20
4-Antibody AG. (1/29/13). "Press Release: 4-Antibody AG and the Ludwig Institute Expand Oncology Antibody R&D Program with Three New Targets". Basel & New York, NY. 2013-01-29
4-Antibody AG. (10/8/12). "Press Release: 4-Antibody AG Receives Additional Milestone Payments from Human Genome Sciences". Basel. 2012-10-08
4-Antibody AG. (3/16/10). "Press Release: 4-Antibody Announces Long-term Collaboration with Boehringer Ingelheim for Therapeutic Antibodies". Basel. 2010-03-16
4-Antibody AG. (8/16/11). "Press Release: 4-Antibody AG Forms Collaboration with Human Genome Sciences". Basel. 2011-08-16
4-Antibody AG. (9/11/09). "Press Release: Retrocyte Display Technology Patent Applications Published". Basel. 2009-09-11
4-Antibody AG. (9/19/11). "Press Release: 4-Antibody AG Meets Next Milestone in Boehringer Ingelheim Collaboration". Basel. 2011-09-19
4-Antibody AG. (9/21/09). "Press Release: 4-Antibody Received Notice of Allowance for U.S. Patent Application Describing the Hu-PAC Technology". Basel. 2009-09-21
4D Molecular Therapeutics. (4/30/18). "Press Release: 4DMT and Roche Expand Ophthalmology Partnership to Develop and Commercialize Multiple AAV Gene Therapy Products". Emeryville, CA. 2018-04-30
4DCell Fate Project. (2/13/12). "Press Release: Cell Fate in 4D. Bringing together European Excellence to Uncover the Mechanisms at Work that Determine Cell Fate". Barcelona. 2012-02-13
4SC AG. (1/12/15). "Press Release: Prof. Dr. Helga Rübsamen-Schaeff and Joerg von Petrikowsky Join the Supervisory Board of 4SC AG". Planegg-Martinsried. 2015-01-12
4SC AG. (1/13/15). "Press Release: Beyond Research Initiative of 4SC Discovery and Crelux Reaches First Milestone in Drug Discovery Project for Helmholtz Zentrum München". Planegg-Martinsried & Munich. 2015-01-13
4SC AG. (1/19/12). "Press Release: 4SC’s Cancer Compound Resminostat Meets Primary Endpoint in Phase II Trial in Advanced Liver Cancer (HCC) ahead of Schedule". Planegg-Martinsried. 2012-01-19
4SC AG. (1/20/11). "Press Release: 4SC Announces First Patient Dosed in Phase I/II SHORE Study in KRAS-mutant Colorectal Cancer Patients with Resminostat". Planegg-Martinsried. 2011-01-20
4SC AG. (1/21/11). "Press Release: 4SC Presents Update on Phase II SHELTER Trial with Oral Pan-HDAC Resminostat at the 2011 Gastrointestinal Cancer Symposium". Planegg-Martinsried. 2011-01-21
4SC AG. (1/23/15). "Press Release: 4SC AG Plans Extraordinary General Meeting and Reduction of Share Capital". Planegg-Martinsried. 2015-01-23
4SC AG. (1/7/11). "Press Release: 4SC Announces First-in-Man Phase I Results for 4SC-203". Planegg-Martinsried. 2011-01-07
4SC AG. (1/8/13). "Press Release: 4SC Obtains Key Patent for Anti-cancer Compound Resminostat in Europe". Planegg-Martinsried. 2013-01-08
4SC AG. (10/1/12). "Press Release: 4SC Obtains Key Patent for Anti-cancer Compound Resminostat in China". Planegg-Martinsried. 2012-10-01
4SC AG. (10/10/17). "Press Release: Resminostat Demonstrates Potential to Significantly Alleviate Itching in CTCL Patients". Planegg-Martinsried. 2017-10-10
4SC AG. (10/21/16). "Press Release: Dr Daniel Vitt to Step Down as CDO/CSO and from the Management Board at the End of 2016". Planegg-Martinsried. 2016-10-21
4SC AG. (10/23/12). "Press Release: 4SC Discovery Receives Research Grant of EUR 600,000 for Development of Personalised Cancer Drugs". Planegg-Martinsried. 2012-10-23
4SC AG. (10/26/10). "Press Release: 4SC Announces Initial Phase II Data from the SAPHIRE Study with Resminostat at the 8th International Symposium on Hodgkin Lymphoma". Planegg-Martinsried. 2010-10-26
4SC AG. (10/26/17). "Press Release: 4SC Provides Q3 and 9M 2017 Update". Planegg-Martinsried. 2017-10-26
4SC AG. (11/11/10). "Press Release: 4SC Reports First Nine Months Financial Results 2010". Planegg-Martinsried. 2010-11-11
4SC AG. (11/16/10). "Press Release: 4SC to Highlight the Potential of Its Oncology Compounds at the 22nd EORTC-NCI-AACR Symposium »on Molecular Targets and Cancer Therapeutics«". Planegg-Martinsried. 2010-11-16
4SC AG. (11/4/10). "Press Release: 4SC’s Vidofludimus Meets Primary Endpoint with Excellent Response Rate in IBD Trial. Vidofludimus Generates a Response Rate of 88.5% for the Treatment of Patients with Crohn’s Disease and Ulcerative Colitis". Planegg-Ma 2010-11-04
4SC AG. (11/4/13). "Press Release: AiCuris, 4SC Discovery and Crelux Announce Drug Discovery Collaboration". Planegg-Martinsried & Wuppertal. 2013-11-04
4SC AG. (11/6/14). "Press Release: 4SC Announces Financial Results for the First Nine Months and the Third Quarter of 2014". Planegg-Martinsried. 2014-11-06
4SC AG. (11/7/11). "Press Release: 4SC Presents Encouraging Final Results of Vidofludimus Phase IIb COMPONENT Study in Rheumatoid Arthritis at ACR Meeting in Chicago". Planegg-Martinsried. 2011-11-07
4SC AG. (11/7/13). "Press Release: 4SC Announces Improved Financial Results for the Third Quarter and First Nine Months of 2013". Planegg-Martinsried. 2013-11-07
4SC AG. (11/8/11). "Press Release: 4SC Announces Financial Results for the Third Quarter and First Nine Months of 2011". Planegg-Martinsried. 2011-11-08
4SC AG. (11/8/12). "Press Release: 4SC’s Successful Development Continues in Third Quarter of 2012. Consolidated Financial Results Improved in Third Quarter and First Nine Months". Planegg-Martinsried. 2012-11-08
4SC AG. (12/12/12). "Press Release: 4SC Announces Positive Interim Results from Clinical Phase I/II Trial with Anti-cancer Compound Resminostat in Colorectal Cancer". Planegg-Martinsried. 2012-12-12
4SC AG. (12/14/11). "Press Release: 4SC Forms Subsidiary to Commercialise Innovative Early-stage Drug Research Programmes and Strengthen Revenue from Research Collaborations". Planegg-Martinsried. 2011-12-14
4SC AG. (12/17/12). "Press Release: 4SC Discovery and BioNTech Announce Exclusive Research and License Agreement for 4SC’s TLR Agonists for Cancer Immunotherapy". Planegg-Martinsried & Mainz. 2012-12-17
4SC AG. (12/20/10). "Press Release: 4SC Completes Enrolment of the Phase IIb COMPONENT Trial with Vidofludimus in Rheumatoid Arthritis". Planegg-Martinsried. 2010-12-20
4SC AG. (12/22/10). "Press Release: 4SC Receives EU Grant to Identify New Drugs for the Treatment of Rheumatoid Arthritis as Part of a Consortium". Planegg-Martinsried. 2010-12-22
4SC AG. (12/7/11). "Press Release: 4SC Obtains Key Patent for Lead Anti-cancer Compound Resminostat in Japan". Planegg-Martinsried. 2011-12-07
4SC AG. (12/9/14). "Press Release: 4SC Reports Positive Topline Data from Clinical Phase I Trial with 4SC-205 in Cancer Patients Using Novel Continuous Dosing Scheme". Planegg-Martinsried. 2014-12-09
4SC AG. (2/1/18). "Press Release: Positive DSMB Safety Review of 4SC’s Pivotal RESMAIN Study of Resminostat in CTCL". Planegg-Martinsried. 2018-02-01
4SC AG. (2/10/15). "Press Release: 4SC's Associated Company Panoptes Pharma Concludes License Agreement with Mediolanum for Compound PP-001 for Inflammatory Eye Diseases". Planegg-Martinsried. 2015-02-10
4SC AG. (2/12/14). "Press Release: Continued Funding of 4SC AG. Investor Undertakes to Subscribe to Convertible Notes for up to EUR 15 Million Nominally [Ad hoc Announcement] ". Planegg-Martinsried. 2014-02-12
4SC AG. (2/20/13). "Press Release: 4SC Discovery and BioNTech Launch Strategic Cancer Therapy Research Partnership". Planegg-Martinsried & Mainz. 2013-02-20
4SC AG. (2/23/11). "Press Release: 4SC Announces Capital Increase". Planegg-Martinsried. 2011-02-23
4SC AG. (2/26/13). "Press Release: 4SC Discovery and Leo Pharma Announce Exclusive Research and License Agreement for Inflammatory Skin Diseases". Planegg-Martinsried & Ballerup. 2013-02-26
4SC AG. (2/6/17). "Press Release: 4SC AG to Present at the 19th Annual BIO CEO & Investor Conference 2017". Planegg-Martinsried. 2017-02-06
4SC AG. (3/1/12). "Press Release: 4SC Receives Patent Protection for Its Oncology Compound Resminostat in Taiwan and Three other Asian Growth Markets". Planegg-Martinsried. 2012-03-01
4SC AG. (3/12/13). "Press Release: Ad hoc. Notice of Loss Pursuant to Section 92 (1) German Stock Corporation Act (Aktiengesetz, AktG)". Planegg-Martinsried. 2013-03-12
4SC AG. (3/20/14). "Press Release: 4SC Discovery Collaborates with Heidelberg University Hospital and Receives EUR 1.3 Million for Research and Preclinical Development of New Malaria Drug". Planegg-Martinsried. 2014-03-20
4SC AG. (3/21/18). "Press Release: 4SC AG Announces Results for Financial Year 2017". Planegg-Martinsried. 2018-03-21
4SC AG. (3/24/16). "Press Release: Chairman of the Management Board Enno Spillner Will Not Extend His Current Term of Office, But Will Leave the Company After a Transitional Period Ending 30 June 2016". Planegg-Martinsried. 2016-03-24
4SC AG. (3/25/13). "Press Release: 4SC Announces Financial Results for a Successful Year 2012". Planegg-Martinsried. 2013-03-25
4SC AG. (3/25/15). "Press Release: 4SC Publishes Results for Financial Year 2014". Planegg-Martinsried. 2015-03-25
4SC AG. (3/26/14). "Press Release: 4SC Publishes Results for Financial Year 2013 and Announces Changes to the Management Board". Planegg-Martinsried. 2014-03-26
4SC AG. (3/27/18). "Press Release: Yakult Honsha Joins 4SC’s Pivotal RESMAIN Study of Resminostat in CTCL – 4SC Receives Milestone Payment". Planegg-Martinsried. 2018-03-27
4SC AG. (3/29/12). "Press Release: 4SC Announces Financial Results 2011". Planegg-Martinsried. 2012-03-29
4SC AG. (3/30/16). "Press Release: 4SC Announces Results for Financial Year 2015". Planegg-Martinsried. 2016-03-30
4SC AG. (3/4/14). "Press Release: 4SC AG Issues First Tranche of Convertible Notes with a Nominal amount of EUR 500,000 to Yorkville". Planegg-Martinsried. 2014-03-04
4SC AG. (3/6/13). "Press Release: 4SC AG. Dr Ulrich Dauer to Step Down as CEO and Member of the Management Board on 31 March 2013, His Successor Will Be CFO Enno Spillner". Planegg-Martinsried. 2013-03-06
4SC AG. (4/1/15). "Press Release: Dr Susanne Danhauser-Riedl Joins 4SC as Chief Medical Officer to Strengthen Management and Clinical Development Team". Planegg-Martinsried. 2015-04-01
4SC AG. (4/11/18). "Press Release: Yakult Honsha Recruits First Japanese Patient in 4SC’s Pivotal RESMAIN Study of Resminostat in CTCL". Planegg-Martinsried. 2018-04-11
4SC AG. (4/14/11). "Press Release: 4SC and Yakult Hinsha Announce Exclusive License Agreement for Japan for the Oral HDAC Inhibitor Resminostat". Planegg-Martinsried & Tokyo. 2011-04-14
4SC AG. (4/14/15). "Press Release: 4SC Signs Licensing and Development Agreement with Menarini for Resminostat in Asia-Pacific Excluding Japan". Planegg-Martinsried & Singapore. 2015-04-14
4SC AG. (4/15/14). "Press Release: 4SC Discovery Receives EU Grant Worth EUR 450,000 for the Research of New Epigenetic Compounds against Stroke". Planegg-Martinsried. 2014-04-15
4SC AG. (4/17/18). "Press Release: 4SC at AACR – Broadened Clinical Options for 4SC-202". Planegg-Martinsried. 2018-04-17
4SC AG. (4/18/12). "Press Release: 4SC Discovery and Crelux Enter into a Strategic Alliance for Joint Drug Discovery Services". Planegg-Martinsried. 2012-04-18
4SC AG. (4/19/18). "Press Release: Phase II Study of 4SC’s Resminostat in Biliary Tract Cancer in Japan Is Initiated". Planegg-Martinsried. 2018-04-19
4SC AG. (4/2/12). "Press Release: Henkel and 4SC Discovery Start Research Collaboration in Compound Screening". Planegg-Martinsried. 2012-04-02
4SC AG. (4/29/16). "Press Release: 4SC Sells Operations of Its Discovery Division [Ad hoc announcement according to $ 15 WpHG]". Planegg-Martinsried. 2016-04-29
4SC AG. (4/30/12). "Press Release: 4SC Receives Milestone Payment from Research Collaboration with SKK". Planegg-Martinsried. 2012-04-30
4SC AG. (5/10/11). "Press Release: 4SC Announces Financial Results for the First Quarter 2011". Planegg-Martinsried. 2011-05-10
4SC AG. (5/14/13). "Press Release: 4SC Significantly Improves Operating Result in First Quarter of 2013 and Resolves to Focus Its Development Strategy". Planegg-Martinsried. 2013-05-14
4SC AG. (5/27/16). "Press Release: 4SC Provides Headline Results from Yakult Honsha’s Phase II Trial of Resminostat in Combination with Sorafenib as First Line Therapy in Liver Cancer (Ad hoc announcement according to § 15 WpHG)". Planegg-Martinsried. 2016-05-27
4SC AG. (5/30/13). "Press Release: 4SC Gives Update on the Clinical Development of Its Lead Cancer Compound Resminostat". Planegg-Martinsried. 2013-05-30
4SC AG. (5/31/16). "Press Release: 4SC Enters into Licensing and Development Partnership with Link Health for the Cancer Compound 4SC-205 in China". Planegg-Martinsried. 2016-05-31
4SC AG. (5/8/14). "Press Release: 4SC Announces Financial Results for the First Quarter of 2014". Planegg-Martinsried. 2014-05-08
4SC AG. (5/9/11). "Press Release: 4SC’s Vidofludimus Inhibits IL-17 Production by Interference with the JAK/STAT and NF-kB Pathways". Planegg-Martinsried. 2011-05-09
4SC AG. (6/11/13). "Press Release: UCB to Collaborate with Crelux and 4SC Discovery to Meet Unmet Needs in Neurology". Planegg-Martinsried & Brussels. 2013-06-11
4SC AG. (6/20/13). "Press Release: 4SC Announces Restructuring Associated with Recently Declared Strategic Shift". Planegg-Martinsried. 2013-06-20
4SC AG. (6/23/11). "Press Release: 4SC Reports New Data from the Clinical Trials with Oral Pan-HDAC Inhibitor Resminostat. Update on Phase II SHELTER and Phase I/II SHORE Trials". Planegg-Martinsried. 2011-06-23
4SC AG. (6/29/12). "Press Release: 4SC AG Capital Increase. Subscription Offer Period Ended, Rump Placement Started [not for USA, Australia, Canada, Japan et al.]". Planegg-Martinsried. 2012-06-29
4SC AG. (6/29/12). "Press Release: 4SC AG. Volume of the Capital Increase Has Been Determined at 8,403,510 New Shares, Gross Proceeds of EUR 12,605,265.00 Expected [not for USA, Australia, Canada, Japan et al.]". Planegg-Martinsried. 2012-06-29
4SC AG. (6/5/14). "Press Release: 4SC Secures Financing with Shareholder Loan of up to EUR 10 Million". 2014-06-05
4SC AG. (6/8/11). "Press Release: 4SC Announces Topline Results of Phase IIb Trial of Vidofludimus in Rheumatoid Arthritis". Planegg-Martinsried. 2011-06-08
4SC AG. (7/12/11). "Press Release: FDA Grants Orphan Drug Designation to 4SC’s Oral Pan-HDAC Inhibitor Resminostat for the Treatment of Hepatocellular Carcinoma". Planegg-Martinsried. 2011-07-12
4SC AG. (7/17/12). "Press Release: 4SC Discovery, Crelux and Ribological Launch Collaboration for the Discovery and Optimisation of New Anti-cancer Drugs [no US". Planegg-Martinsried. 2012-07-17
4SC AG. (7/18/17). "Press Release: 4SC Licenses Kv1.3 Inhibitors to Maruho. Maruho to Receive Exclusive Worldwide License on 4SC’s Preclinical Inhibitors of the Kv1.3 Ion Channel". Planegg-Martinsried. 2017-07-18
4SC AG. (7/20/16). "Press Release: 4SC Forms International Scientific Expert Panel". Planegg-Martinsried. 2016-07-20
4SC AG. (7/24/14). "Press Release: Crelux and 4SC Discovery Awarded Research Grant for New Epigenetic Cancer Drugs. Project for Identifying New Bromodomain Inhibitors Initiated under the Munich m4 Biotech Cluster Programme". Planegg-Martinsried. 2014-07-24
4SC AG. (7/26/11). "Press Release: European Medicines Agency Adopts Positive Opinion for Orphan Medicinal Product Designation for 4SC’s Resminostat to Treat Hepatocellular Carcinoma". 2011-07-26
4SC AG. (7/29/15). "Press Release: 4SC AG Announces Formal Closing of Capital Increase [Not for United States, Australia, Canada or Japan]". Planegg-Martinsried. 2015-07-29
4SC AG. (7/6/17). "Press Release: 4SC AG Secures EUR 41 Million from Successful Capital Increase [Not for US, AU, CA, JP or ZA]". Planegg-Martinsried. 2017-07-06
4SC AG. (7/7/15). "Press Release: 4SC AG Secures EUR 29 Million from Capital Increase to Finance Planned Clinical Development Programme of Its Cancer Compound Resminostat [ Ad hoc release, not for US, AU, CA or JP]". Planegg-Martinsried. 2015-07-07
4SC AG. (8/1/17). "Press Release: 4SC AG Was Granted a Fundamental Composition of Matter Patent for 4SC-208 for the US". Planegg-Martinsried. 2017-08-01
4SC AG. (8/11/16). "Press Release: 4SC Provides Operational and Financial Update for Q2 and 6M 2016". Planegg-Martinsried. 2016-08-11
4SC AG. (8/18/14). "Press Release: Dr Thomas Werner und Klaus Kühn Announce Resignation for Supervisory Board". 2014-08-18
4SC AG. (8/6/12). "Press Release: 4SC AG further Strengthens Supervisory Board with Experienced Managers from the Pharmaceutical Industry [Not for US, AU, CA, JP et al.]". Planegg-Martinsried. 2012-08-06
4SC AG. (8/7/14). "Press Release: 4SC Announces Financial Results for the First Half of 2014". Planegg-Martinsried. 2014-08-07
1 2 3 ... 97 98 99  next pagenext page



Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x60px

» top